Paolo Fusco

Once-weekly oral islatravir plus lenacapavir: clinical considerations for individualized use

Once-weekly oral islatravir plus lenacapavir represents a promising strategy to expand treatment choice for people with HIV (PWH) who prefer oral therapy without daily dosing. Phase 2 findings provide reassuring evidence of maintained virological suppression and support further c...